These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 28050755)

  • 21. National Trends in Ambulatory Oral Anticoagulant Use.
    Barnes GD; Lucas E; Alexander GC; Goldberger ZD
    Am J Med; 2015 Dec; 128(12):1300-5.e2. PubMed ID: 26144101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct oral anticoagulants in rare venous thrombosis.
    Finazzi G; Ageno W
    Intern Emerg Med; 2016 Mar; 11(2):167-70. PubMed ID: 26875179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Laboratory assessment of the direct oral anticoagulants: who can benefit?
    Akpan IJ; Cuker A
    Kardiol Pol; 2021; 79(6):622-630. PubMed ID: 34029374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
    Malec K; Góralczyk T; Undas A
    Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions.
    Sadlon AH; Tsakiris DA
    Swiss Med Wkly; 2016; 146():w14356. PubMed ID: 27683276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.
    Comerota AJ; Ramacciotti E
    Am J Med Sci; 2016 Jul; 352(1):92-106. PubMed ID: 27432042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 29. Direct Oral Anticoagulants in Obesity: An Updated Literature Review.
    Sebaaly J; Kelley D
    Ann Pharmacother; 2020 Nov; 54(11):1144-1158. PubMed ID: 32443941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversal Agents for Direct Oral Anticoagulants: Understanding New and Upcoming Options.
    Rogers KC; Shelton MP; Finks SW
    Cardiol Rev; 2016; 24(6):310-315. PubMed ID: 27548686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dilemmas Related to Direct-Acting Oral Anticoagulant Administration in Patients With Extreme Obesity.
    Erstad BL; Barletta JF
    Ann Pharmacother; 2023 Jun; 57(6):727-737. PubMed ID: 36258660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
    Elewa H; El-Makaty H; Ali Z
    J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):155-161. PubMed ID: 28978236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study.
    Viktil KK; Lehre I; Ranhoff AH; Molden E
    Drugs Aging; 2019 Jan; 36(1):65-71. PubMed ID: 30411284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
    Gous T; Couchman L; Patel JP; Paradzai C; Arya R; Flanagan RJ
    Ther Drug Monit; 2014 Oct; 36(5):597-605. PubMed ID: 24695356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in oral anticoagulant use in Qatar: a 5-year experience.
    Elewa H; Alhaddad A; Al-Rawi S; Nounou A; Mahmoud H; Singh R
    J Thromb Thrombolysis; 2017 Apr; 43(3):411-416. PubMed ID: 28138812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.
    Kustos SA; Fasinu PS
    Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31618893
    [No Abstract]   [Full Text] [Related]  

  • 37. Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.
    Benamouzig R; Guenoun M; Deutsch D; Fauchier L
    Cardiovasc Drugs Ther; 2022 Oct; 36(5):973-989. PubMed ID: 34143317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
    Favaloro EJ; Mohammed S; Curnow J; Pasalic L
    Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence.
    Willett KC; Morrill AM
    Ther Clin Risk Manag; 2017; 13():447-454. PubMed ID: 28435279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed.
    Milling TJ; Spyropoulos AC
    Am J Med; 2016 Nov; 129(11S):S54-S63. PubMed ID: 27569671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.